01.08.2014 • TopicsCMI 04/13

Pharmaceutical Lifecycle Management

Pharmaceutical Lifecycle Management
Pharmaceutical Lifecycle Management

This book systematically explains how LCM strategies can help the pharmaceutical industry maximize the value of its patented brands through effective drug development programs and brand management. The authors share their combined 50 years of experience in the industry, citing numerous recent examples and case histories, and demonstrating how different measures can be combined to create winning strategies. The text helps pharmaceutical professionals understand challenges facing the industry and the role LCM has in confronting them, and offers a look ahead to predict which LCM strategies will continue to be effective in the future.

Pharmaceutical Lifecycle Management
Tony Ellery, Neal Hansen
John Wiley & Sons
Price: € 77,90
ISBN 13: 978-0-470-48753-2

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
19.03.2025 • TopicsStrategy

The Future of Demand for Chemicals

The chemical industry is shifting to sustainability-related products, with demand growing 4.5 times faster than conventional ones. Companies must revise their market strategies to capitalize on this opportunity.

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.